R&D
We contribute to promoting human health.
We are the global leader in stem cell therapies
EHL Bio is a company that develops adult stem cell therapies that continuously research for the beautiful and healthy future of humanity by striving to take a step further in conquering incurable diseases with innovative development of cell therapies using adult stem cells with multi-differentiation ability. Based on our unique technology, we are doing stem cell treatment business tailored to patients using stem cells.
Possesses original technology of separate culture of fat stem cells
Promote customer convenience by establishing more than 100 cooperative hospitals in Korea
Stem cell treatment available at over 50 partner hospitals overseas
Atopic dermatitis therapeutics (ADSTEM)
Parkinson's disease therapeutics (PDSTEM)
Rheumatoid arthritis therapeutics (RASTEM)
Chronic renal failure therapeutics (KDSTEM)
ADSTEM inj.
ADSTEM Inj. Is an autologous adipose-derived mesenchymal stem cell therapy drug that is being developed for patients with moderate to severe subacute and chronic atopic dermatitis. The first phase of ADSTEM Inj.’s clinical trials has been completed and the second phase of clinical trials is currently being conducted at five hospitals including Chung-Ang University Hospital.
Product name : ADSTEM Inj.
Manufacturer : EHL Bio Co.,Ltd
Target efficacy effect : Treatment of moderate to severe subacute and chronic atopic dermatitis
Method of injection : Intravenous injection, repeated administration twice
RASTEM inj.
RASTEM Inj. Is an autologous adipose-derived mesenchymal stem cell therapy drug that is being developed for patients with moderate or more rheumatoid arthritis. RASTEM Inj. Is currently completing a non-clinical study and is preparing for a clinical trial.
Product name : RASTEM Inj.
Manufacturer : EHL Bio Co.,Ltd
Target efficacy effect : Treatment of moderate or more rheumatoid arthritis
Method of injection : Intravenous injection, repeated administration
PDSTEM inj.
PDSTEM Inj. Is an autologous adipose-derived mesenchymal stem cell treatment and is being developed for patients with Parkinson's disease. PDSTEM Inj. Is currently in non-clinical progress.
Product name : PDSTEM Inj.
Manufacturer : EHL Bio Co.,Ltd
Target efficacy effect : Treatment of Parkinson's disease.
Method of injection : Intravenous injection, repeated administration
KDSTEM inj.
KDSTEM Inj. Is a treatment for autologous urine-derived mesenchymal stem cells and is being developed for patients with chronic renal failure. Urine-derived stem cells express Klotho. Klotho is known as a representative "anti-aging protein" because it plays a role in antioxidant, cell aging suppression, angiogenesis, and human metabolism regulation. KDSTEM Inj. Is currently undergoing non-clinical studies.
Product name : KDSTEM Inj.
Manufacturer : EHL Bio Co.,Ltd
Target efficacy effect : Treatment of chronic renal failure
Method of injection : Intravenous injection, repeated administration
